规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | GANT61 (20 μM) induces more significant cell death compared to targeting Smo (cyclopamine). It also inhibits the clonogenic survival of human colon carcinoma cell lines (0, 5, 10, 20 μM). Moreover, GANT61 (20 μM, 0-72 hr) downregulates Gli1 and Gli2 expression in HT29 cells. Additionally, GANT61 (0, 10 μM, or 20 μM) differentially regulates genes involved in the balance between cell death and survival[1]. GANT-61 inhibits cell viability and induces apoptosis in pancreatic CSCs. It also suppresses the expression of downstream targets of the Shh pathway, decreases Gli-DNA interaction, Gli transcriptional activity, and Gli nuclear translocation in pancreatic CSCs. Furthermore, GANT-61 modulates genes associated with cell survival, cell death, and pluripotency, while also inhibiting the motility, invasion, and migration of CSCs[2]. The sensitivity of GANT61 correlates positively with GLI1 and negatively with MYCN expression in the tested neuroblastoma cell lines. GANT61 downregulates the expression of GLI1, c-MYC, MYCN, and Cyclin D1, and induces apoptosis in neuroblastoma cells[3]. |
体内研究 | Administered at a dose of 40 mg/kg via intraperitoneal injection three days per week, GANT-61 inhibits CSC tumor growth in NOD/SCID IL2Rγ null mice[2]. Furthermore, GANT61 (50 mg/kg, per oral) enhances the effects of chemotherapeutic drugs used in neuroblastoma treatment in an additive or synergistic manner. It also reduces the growth of established neuroblastoma xenografts in nude mice[3]. |
体外研究 | GANT61 (20 μM) induces more significant cell death compared to targeting Smo (cyclopamine). It also inhibits the clonogenic survival of human colon carcinoma cell lines (0, 5, 10, 20 μM). Moreover, GANT61 (20 μM, 0-72 hr) downregulates Gli1 and Gli2 expression in HT29 cells. Additionally, GANT61 (0, 10 μM, or 20 μM) differentially regulates genes involved in the balance between cell death and survival[1]. GANT-61 inhibits cell viability and induces apoptosis in pancreatic CSCs. It also suppresses the expression of downstream targets of the Shh pathway, decreases Gli-DNA interaction, Gli transcriptional activity, and Gli nuclear translocation in pancreatic CSCs. Furthermore, GANT-61 modulates genes associated with cell survival, cell death, and pluripotency, while also inhibiting the motility, invasion, and migration of CSCs[2]. The sensitivity of GANT61 correlates positively with GLI1 and negatively with MYCN expression in the tested neuroblastoma cell lines. GANT61 downregulates the expression of GLI1, c-MYC, MYCN, and Cyclin D1, and induces apoptosis in neuroblastoma cells[3]. |
Concentration | Treated Time | Description | References | |
MCF7-Ctrl | 10 µM | 48 h | Restores EMT marker expression, inhibits invasion | Nat Commun. 2017 Jun 12;8:15773. |
HMLER-Ctrl | 10 µM | 48 h | Inhibits GLI signaling activation, reduces migration and invasion | Nat Commun. 2017 Jun 12;8:15773. |
AML cell lines | 20 μM | 24 h | Induced apoptosis, resulting in approximately 30% of cells undergoing apoptosis | J Hematol Oncol. 2017 Jan 21;10(1):26. |
PANC-1 | 30 μM | 3 days | GANT61 had a more modest effect on the viability and sphere formation of PANC-1 cells, but still significantly reduced cell viability at 30 μM. | Mol Cancer. 2016 Jun 27;15(1):49. |
Capan-1 M9 | 20 μM | 3 days | Inhibition of the Hh pathway significantly reduced the expression of stem cell marker CD133 and sphere formation, demonstrating the suppression of CSC-like properties. GANT61 was more effective than the SMO inhibitor cyclopamine in reducing sphere formation and cell viability. | Mol Cancer. 2016 Jun 27;15(1):49. |
Human mesenchymal stem cells | 10 μM | 24-48 h | To investigate the effect of GANT61 on mesenchymal stem cells from MPN patients and healthy donors, results showed that GANT61 significantly reduced the expression of α-SMA and Gli1, and induced apoptosis in MPN-MSCs. | Cell Stem Cell. 2017 Jun 1;20(6):785-800.e8. |
NCI-H1299 cells | 10, 20, and 30 μM | Inhibited the migration and invasion abilities of NCI-H1299 cells | Acta Pharm Sin B. 2022 Oct;12(10):3877-3890. | |
HT29 cells | 20 µM | 72 h | GANT61 induced accumulation of HT29 cells at G1/S and early S-phase, followed by entry into subG1, leading to cell death. | Cancer Res. 2011 Sep 1;71(17):5904-14. |
WB-F344 cells | 2 μM | 4 days | Inhibition of Gli1 expression reduced the expression of KRT19 and Ki67, as well as proinflammatory cytokines including IL-6 and TNF-α, thereby suppressing the differentiation of HPCs into cholangiocytes. | Theranostics. 2024 Mar 25;14(6):2379-2395. |
Administration | Dosage | Frequency | Description | References | ||
Nude mice | Capan-1 M9 xenograft model | Intraperitoneal injection | 40 mg/kg | 3 times a week for 25 days | Combination treatment with GANT61 and the mTOR inhibitor rapamycin significantly inhibited tumor growth in the Capan-1 M9 xenograft model. | Mol Cancer. 2016 Jun 27;15(1):49. |
Mice | Jak2(V617F)-induced myelofibrosis model | Subcutaneous injection | 50 mg/kg | Every other day for 9 weeks | To investigate the therapeutic effect of GANT61 on Jak2(V617F)-induced myelofibrosis, results showed that GANT61 significantly reduced the number of Gli1+ cells, inhibited the development of bone marrow fibrosis, and improved splenomegaly and hemoglobin levels. | Cell Stem Cell. 2017 Jun 1;20(6):785-800.e8. |
BALB/c nude mice | NSCLC metastasis model | Intraperitoneal injection | 50 mg/kg | Every two days for a total of 30 days | GANT-61 significantly suppressed the lung and liver metastasis of NSCLC | Acta Pharm Sin B. 2022 Oct;12(10):3877-3890. |
Mice | Breast cancer xenograft model | Subcutaneous injection | 50 mg/kg | Every other day for 18 days | Inhibits metastasis and growth of non-EMT cells | Nat Commun. 2017 Jun 12;8:15773. |
Mice | Unilateral ureteral obstruction model | Subcutaneous injection | 50 mg/kg | Administered on days 1, 2, 3, 5, 7, and 9 after surgery | GANT61 reduced renal fibrosis by decreasing GLI1 and GLI2 protein levels. | J Clin Invest. 2015 Aug 3;125(8):2935-51 |
Nude mice | NSCLC xenograft model | Intraperitoneal injection | 50 mg/kg | Every other day for 24 days | To evaluate the effect of GANT61 on tumor angiogenesis and tumor growth in NSCLC, the results showed that GANT61 significantly inhibited tumor angiogenesis and tumor growth. | J Exp Clin Cancer Res. 2024 Mar 16;43(1):83 |
Dose | Nude Mice: 25 mg/kg[3] (s.c.), 50 mg/kg[4] (p.o.) |
Administration | s.c., p.o. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.33mL 0.47mL 0.23mL |
11.64mL 2.33mL 1.16mL |
23.28mL 4.66mL 2.33mL |
CAS号 | 500579-04-4 |
分子式 | C27H35N5 |
分子量 | 429.6 |
SMILES Code | CN(C)C1=CC=CC=C1CN2C(C3=CC=NC=C3)N(CC4=CC=CC=C4N(C)C)CCC2 |
MDL No. | MFCD14635408 |
别名 | |
运输 | 蓝冰 |
InChI Key | KVQOGDQTWWCZFX-UHFFFAOYSA-N |
Pubchem ID | 421610 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
溶解方案 |
DMSO: 25 mg/mL(58.19 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 60 mg/mL(139.66 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|